AL
SAGE

Airain Ltd’s Sage Therapeutics SAGE Stock Holding History

Airain Ltd’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$1.38M Buy
+17,281
New +$1.25M 0.06% 349

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Airain Ltd's SAGE Position: Q2 2017 in Review

Airain Ltd opened a new position in Sage Therapeutics (SAGE) in Q2 2017: 17,281 shares worth $1.38M. The stake represents 0.06% of the portfolio and ranks #349 among its holdings.

190 funds tracked by Wall St. Rank hold SAGE as of Q2 2017.

  • Airain Ltd held 17,281 shares of Sage Therapeutics worth $1.38M as of Q2 2017.
  • Sage Therapeutics was a new Airain Ltd position in Q2 2017.
  • Sage Therapeutics made up 0.06% of Airain Ltd's portfolio in Q2 2017, its #349 holding.
  • 190 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2017.

Based on Airain Ltd's 13F filing for Q2 2017, filed 8 Aug 2017.